Bioactive food peptides are encrypted within the source protein but can exert 16 physiological properties once released by enzymatic hydrolysis during gastrointestinal transit, 17 fermentation or maturation during food processing, or proteolysis by food-grade enzymes derived 18 from microorganisms or plants. Among the bioactive food peptides, those with antihypertensive 19 activity are receiving special attention due to the high prevalence of hypertension in the Western 20 countries and its role in cardiovascular diseases. This paper reviews the current literature on 21
as enzymatic hydrolysis, fermentation and genetic recombination in bacteria. This paper also 23 evaluates the structure/activity relationship of angiotensin-converting enzyme (ACE) inhibitory 24 peptides, as well as their bioavailability, physiological effects demonstrated by both in vitro and 25 in vivo assays, and the existence of mechanisms of action other than ACE inhibition. Finally, 26 current reported strategies for incorporation of antihypertensive peptides in foods and their 27 effects on both availability and activity of these peptides are revised in this manuscript. 28 inhibitory activity is generally measured by monitoring the conversion of an appropriate substrate 197 by ACE in the presence and absence of the potential inhibitors. There are several methods, but 198 those based on spectrophotometric and high-performance liquid chromatography (HPLC) assays 199 are most commonly utilized. The spectrophotometric method of Cushman and Cheung [94] is 200 based on the hydrolysis of Hippuryl-His-Leu (HHL) by ACE to hippuric acid and His-Leu, and 201 the extent of hippuric acid released is measured after its extraction with ethyl acetate. The 202 inhibitory potency is expressed as the IC 50 value, or concentration needed to inhibit 50% of the 203 enzyme activity. Extraction of reaction product is tedious and may overestimate ACE activity if 204 unhydrolyzed HHL is also extracted. Another broadly used spectrophotometric method is based 205 in the hydrolysis of a furanocryloyl tripeptide (FAPGG) to FAP and the di-peptides GG [95] . 206
Using HPLC methods, the peak of hippuric acid may be interfered with by the added ACE 207 inhibitors in the reaction mixture, so the mobile phase needs to be adjusted to different tested 208 compounds. Moreover, the HPLC method show lower detection sensitivity and longer analysis 209 time to obtain good results. Doig and Smiley [96] and Mehanna and Dowling [97] been tested in hypertensive humans [48] . This product, containing peptides IPP and VPP, showed 248 to exert a long-term blood pressure-lowering effect after normal daily ingestion during a 21-249 weeks intervention period. 250 251
Structure-activity relationship 252
Although the structure-activity relationship of ACE-inhibitory peptides derived from 253 foods has not yet been fully elucidated, several structural features influencing potency of these 254 peptides have been identified [7, 109] . Recently, it has been reported that artificial neural 255 networks (ANN) and quantitative structure-activity relationship (QSAR) modelling may be used 256 to develop statistical computer models potentially capable of identifying ACE inhibitory peptides 257 based on structure-activity data [110] . Several descriptor variables such as molecular mass and 258 shape, hydrophobicity, charge and electronic properties have been recognized as critical in this 259 QSAR modelling. The majority of ACE inhibitory peptides are relatively short sequences 260 containing from 2 to 12 amino acids. This in agreement with the results of Natesh and coworkers 261
[111], which demonstrated from crystallography studies, that the active site of ACE cannot 262 accommodate large peptide molecules. However, some studies have identified ACE inhibitory 263 peptides with up to 27 amino acids [58, 112, 113] . Of many ACE-inhibitory peptides identified 264 from different food sources, structure-activity correlation indicated that C-terminal tri-peptide 265 residues play a predominant role in competitive binding to the active site of ACE. It has been 266 reported that this enzyme prefers substrates or inhibitors containing hydrophobic (aromatic or 267 branched side chains) amino acid residues at each of the three C-terminal positions. The most 118]. For long chain peptides, it is expected that peptide conformation, i.e. the structure adopted 278 in the specific environment of the binding site, will influence binding to ACE [117, 118] . It has 279 also been demonstrated that ACE has a requirement for the L-configuration of the amino acid at 280 position three from the C-terminal. Moreover, changes in cis-trans conformations of Pro at the C-281 terminal position of an ACE inhibitory peptide may cause significant changes in its interaction 282 with the enzyme [119] . 283 284
Mechanism of action 285
Blood pressure is determined by cardiac output and vascular peripheral resistance, and is 286 regulated by a complex system involving the RAS, the sympathetic nervous system (SNS), and 287 the kidney and fluid balance mechanism [118] . Most food-derived peptides usually display 288 higher in vivo activities than the efficacy levels extrapolated from the in vitro ACE inhibitory 289 activity. This may be an indication of the existence of an additional mode of action [120] . In fact, 290 increasing evidence is being provided that different mechanisms, others than ACE inhibition, are 291 peptides VPP and IPP have been shown to inhibit ACE at micromolar concentrations [40, 41] . In 293 vivo, long-term treatment of spontaneously hypertensive rats with fermented milk containing 294 these peptides has been found to decrease serum ACE activity [121] [122] [123] . However, according to 295 Jauhiainen et al. [54] , the mechanistic theory of ACE inhibition of IPP and VPP remains to be 296 confirmed and other effects have to be taken into consideration. Some of these effects have been 297 evaluated in animal models and clinical studies. Plasma rennin activity and levels have been 298
found to be raised in spontaneously hypertensive rats receiving IPP and VPP for 14 weeks. This 299 raising can be due to the lack of negative feedback by angiotensin II, which supports that ACE 300 was inhibited [47] . Other authors have reported the protective effects exerted by these peptides on 301 endothelial function of isolated mesenteric arteries of rats after 24 h incubation with them [124] . KVLPVPQ is generated by hydrolysis of the glutamine residue at the C-terminal end during 361 pancreatic digestion [140] . This is also the case of the egg-derived antihypertensive peptidesgastrointestinal digestion [11] . The pharmacokinetic behaviour of the tri-peptides IPP and VPP 364 has also been studied and an absolute bioavailability of 0.1% respect the administered dose has 365 been calculated in pigs [141] . In humans, these two tri-peptides were detected in plasma after oral 366 administration at picomolar concentrations and their absorption was enhanced when ingested in 367 the form of an enriched yogurt beverage. In addition, a further increase (1.2-fold) in the plasmatic 368 concentration of IPP was found when the enriched yogurt was administered after a meal [142] . 
Incorporation into food products 380
For an industrial application of protein hydrolyzates containing antihypertensive peptides, 381 main considerations would be the organoleptic characteristics of these ingredients and the 382 evaluation of the resistance of the active peptides to processing conditions. The practical use of 383 protein hydrolyzates in food systems is hindered due to the presence of low molecular weight 384 peptides composed mainly of hydrophobic amino acids that results in a bitter taste [149] . In fact, 385 this problem has limited the use of some of the developed hydrolyzates with proved 386 antihypertensive effect. In addition to the bitterness, the pH of the hydrolysis reaction needs to be 387 regulated because the substrate susceptibility and the enzyme activity are strongly influenced by 388 the pH. In order to achieve the desired hydrolysis degree to obtain biologically active peptides, 389 the addition of some alkali or acid is required to neutralize the hydrolysis products. This leads to 390 undesirable high ash build up in the hydrolyzates and the development of salty off-flavors. 391
Different strategies have been applied for debittering protein hydrolyzates. These include 392 absorption of bitter peptides on activated carbon, chromatographic removal using different 393 matrices and selective extraction with alcohols [149] . The most extended approaches include 394 hydrolysis of bitter peptides with enzymes such as aminopeptidase, alkanine/neutral protease and 395 carboxypeptidase, condensation reactions of bitter peptides using protease and use of 396
Lactobacillus as debittering starter adjunct [150] . However, the application of all these methods 397 in biologically active hydrolyzates is limited because the enzymatic activity used for debittering 398 can hydrolyze the previously generated bioactive peptides. Although it has not been found a 399 significant correlation between bitterness and the ACE-inhibitory activity of di-and tri-peptides 400
[151], it is recognized the importance of hydrophobic amino acid residues for both bitterness and 401 ACE-inhibitory peptides. Therefore, those methods based in the removal of bitter peptides (either 402 absorption, extraction or hydrolysis) have to be carefully applied to hydrolyzates containing, for 403 instance, ACE-inhibitory peptides. For bioactive hydrolyzates, the application of masking 404 methods by using monosodium glutamate or glutamylglutamic acid For instance, it has been reported that an 12 amino acid long antihypertensive peptide can bedigested by exposure to yogurt starter culture strains and therefore, the incorporation of this 434 bioactive peptide should preferably done at the end of the yogurt-making process [166] . 
